This database contains 13 studies, archived under the term: "antiparkinson agents"
Click here to filter this large number of results.
Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson’s disease
Li, Wei,
Zhao, Jian-Hua,
Sun, Sheng-Gang,
Zhang, Jie-Wen,
Suo, Ai-Qin,
Ma, Ming-Ming
Objective: To study the effects of memantine on cognitive and motor impairment in patients with Parkinson’s disease (PD).; Methods: A total of 55 PD patients complicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group (n = 28) received memantine (20 mg/d) while those in the control […]
Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia
Larsson, Victoria,
Engedal, Knut,
Aarsland, Dag,
Wattmo, Carina,
Minthon, Lennart,
Londos, Elisabet
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias.; Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB) over 24 weeks using caregiver-rated QOL-Alzheimer’s disease (AD) in domains according to the […]
Memantine in everyday clinical practice: a comparison of studies in Germany and Greece
Förstl, H.,
Stamouli, S. S.,
Janetzky, W.,
Galanopoulos, A.,
Karageorgiou, C.,
Tzanakaki, M.
Background/aims: Results from German and Greek non-interventional studies were compared to investigate possible differences concerning efficacy, tolerability and compliance between both countries.; Methods: In two open-label, multicentre, non-interventional studies, 4,305 patients with mild to severe Alzheimer’s disease (AD) were treated with daily doses of 20 mg memantine for 6 months. Efficacy was assessed using the […]
Continuous dopaminergic stimulation by Duodopa in advanced Parkinson’s disease: Efficacy and safety
Annic, A.,
Devos, D.,
Seguy, D.,
Dujardin, K.,
Destée, A.,
Defebvre, L.
Introduction: When advanced Parkinson’s disease (PD) patients experience motor complications (fluctuations and dyskinesias) despite standard oral treatment, two treatment options are available: deep brain stimulation and subcutaneous apomorphine infusion with respects of indications for each strategy. Continuous intraduodenal infusion of levodopa (Duodopa) via a gastrojejunal tube may be proposed at this stage of the disease […]
Levodopa response in dementia with lewy bodies: a 1-year follow-up study
Lucetti, Claudio,
Logi, Chiara,
Del Dotto, Paolo,
Berti, Caterina,
Ceravolo, Roberto,
Baldacci, Filippo,
Dolciotti, Cristina,
Gambaccini, Gianna,
Rossi, Giuseppe,
Bonuccelli, Ubaldo
Purpose: To evaluate levodopa responsiveness in patients with probable dementia with Lewy bodies (DLB) compared to early Parkinson’s disease (PD) patients.; Methods: Twenty four cases with DLB and 21 with PD underwent a baseline assessment with UPDRS (sub-item II and III) and an acute levodopa challenge test. Positive response to acute levodopa test was defined […]
Levodopa use and sleep in patients with dementia with Lewy bodies
Sleep disturbance and excessive daytime somnolence (EDS) are features of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) that may be influenced by dopamine replacement therapy. The effect of levodopa on sleep and EDS in DLB is unknown and unclear in PD. The aim of this study is to determine if levodopa treatment alters […]
Efficacy and safety of memantine in Lewy body dementia
Lewy body dementia (LBD) is a progressive brain disease manifest as dementia and parkinsonism, along with psychotic and autonomic disorders. Although studies in recent years have demonstrated the positive effects of cholinesterase inhibitors in LBD, the search for therapeutic agents with other mechanisms of action remains relevant. An open, controlled, 16-week study was performed with […]